Theravance Biopharma, Inc. - TBPH
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 6,657.0 | 17.0342 | 113,396.67 | 213,476.0 | View | |
| Sep 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 3,328.0 | 17.0343 | 56,690.15 | 220,133.0 | View | |
| Sep 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 3,329.0 | 17.0341 | 56,706.52 | 223,461.0 | View | |
| Aug 24, 2026 | CHIEF EXECUTIVE OFFICER | F | D | 20,034.0 | 16.95 | 339,576.3 | 1,611,022.0 | View | |
| Aug 24, 2026 | SVP & CHIEF FINANCIAL OFFICER | F | D | 8,112.0 | 16.95 | 137,498.4 | 336,841.0 | View | |
| Aug 24, 2026 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 6,258.0 | 16.95 | 106,073.1 | 189,826.0 | View | |
| Aug 24, 2026 | SVP, GEN COUNSEL AND SECRETARY | F | D | 7,952.0 | 16.95 | 134,786.4 | 355,168.0 | View | |
| Aug 24, 2026 | SVP, COMM & MEDICAL AFFAIRS | F | D | 5,667.0 | 16.95 | 96,055.65 | 226,790.0 | View | |
| Jul 01, 2026 | — | S | D | 37,799.0 | 17.0012 | 642,628.36 | 9,174,453.0 | View | |
| Jul 01, 2026 | — | S | D | 25,027.0 | 17.133 | 428,787.59 | 9,212,252.0 | View | |
| Jul 01, 2026 | — | S | D | 273,871.0 | 17.2349 | 4,720,139.3 | 9,237,279.0 | View | |
| Jun 23, 2026 | SVP, DEV & HEAD OF IRE OFFICE | A | A | 18,750.0 | 0.0 | 0.0 | 196,084.0 | View | |
| Jun 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 6,657.0 | 16.3856 | 109,078.94 | 232,457.0 | View | |
| Jun 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 3,328.0 | 16.3838 | 54,525.29 | 239,114.0 | View | |
| Jun 17, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 3,329.0 | 16.3902 | 54,562.98 | 242,442.0 | View | |
| Jun 16, 2026 | — | A | A | 13,398.0 | 0.0 | 0.0 | 13,398.0 | View | |
| Jun 16, 2026 | — | A | A | 6,009.0 | 0.0 | 0.0 | 48,146.0 | View | |
| Jun 16, 2026 | — | A | A | 13,398.0 | 0.0 | 0.0 | 13,398.0 | View | |
| Jun 16, 2026 | — | A | A | 6,009.0 | 0.0 | 0.0 | 80,989.0 | View | |
| Jun 16, 2026 | — | A | A | 13,398.0 | 0.0 | 0.0 | 13,398.0 | View | |
| Jun 16, 2026 | — | A | A | 6,009.0 | 0.0 | 0.0 | 97,213.0 | View | |
| Jun 16, 2026 | — | A | A | 13,398.0 | 0.0 | 0.0 | 13,398.0 | View | |
| Jun 16, 2026 | — | A | A | 6,009.0 | 0.0 | 0.0 | 80,213.0 | View | |
| Jun 16, 2026 | — | A | A | 13,398.0 | 0.0 | 0.0 | 13,398.0 | View | |
| Jun 16, 2026 | — | A | A | 6,009.0 | 0.0 | 0.0 | 64,074.0 | View | |
| May 22, 2026 | SVP & CHIEF FINANCIAL OFFICER | F | D | 8,670.0 | 16.55 | 143,488.5 | 344,953.0 | View | |
| May 22, 2026 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 6,827.0 | 16.55 | 112,986.85 | 177,334.0 | View | |
| May 22, 2026 | SVP, GEN COUNSEL AND SECRETARY | F | D | 8,829.0 | 16.55 | 146,119.95 | 363,120.0 | View | |
| May 22, 2026 | SVP, COMM & MEDICAL AFFAIRS | F | D | 5,678.0 | 16.55 | 93,970.9 | 245,771.0 | View | |
| May 22, 2026 | CHIEF EXECUTIVE OFFICER | F | D | 20,038.0 | 16.55 | 331,628.9 | 1,631,056.0 | View | |
| Apr 03, 2026 | SVP, COMM & MEDICAL AFFAIRS | A | A | 18,750.0 | 0.0 | 0.0 | 251,449.0 | View | |
| Apr 03, 2026 | SVP, GEN COUNSEL AND SECRETARY | A | A | 37,500.0 | 0.0 | 0.0 | 371,949.0 | View | |
| Apr 03, 2026 | SVP & CHIEF FINANCIAL OFFICER | A | A | 37,500.0 | 0.0 | 0.0 | 353,623.0 | View | |
| Apr 03, 2026 | CHIEF EXECUTIVE OFFICER | A | A | 75,000.0 | 0.0 | 0.0 | 1,651,094.0 | View |